Inflammation-associated drug resistance and tumor growth in TNBC

Inflammation-associated drug resistance and tumor growth in TNBC

Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of hormone receptors and HER2 amplification. This molecular profile limits the effectiveness of targeted therapies, leaving chemotherapy as the mainstay of treatment...

Full description

Saved in:

Bibliographic Details
Main Authors:	Arij Fouzat Hassan, Hadeel Kheraldine, Lama Abujamous, Hamda Al-Thawadi, Abdelbary Elhissi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	triple-negative breast cancer (TNBC) tumor microenvironment (TME) inflammation cytokines drug resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623137/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

The circDUSP1/miR-429/DLC1 regulatory network affects proliferation, migration, and invasion of triple-negative breast cancer cells
by: Canhui Jian, et al.
Published: (2025-07-01)

Echinochrome A inhibits epithelial–mesenchymal transition and induces cell death mediated by DNA damage in human triple-negative breast cancer cells
by: Soon Yong Park, et al.
Published: (2025-10-01)

Tumor‐stroma interactions differentially alter drug sensitivity based on the origin of stromal cells
by: Benjamin D Landry, et al.
Published: (2018-08-01)

Pharmacological CLK inhibition disrupts SR protein function and RNA splicing blocking cell growth and migration in TNBC
by: Nasi Liu, et al.
Published: (2025-07-01)

Plant polysaccharides in the regulation of the tumor microenvironment: a review
by: Yuhua Li, et al.
Published: (2025-09-01)

CCT196969 inhibits TNBC by targeting the HDAC5/RXRA/ASNS axis to down-regulate asparagine synthesis
by: Qiong Yuan, et al.
Published: (2025-08-01)

Therapeutic limitations of oncolytic VSVd51-mediated miR-199a-5p delivery in triple negative breast cancer models
by: Guillaume St-Cyr, et al.
Published: (2025-05-01)

Resolving tumor microenvironment heterogeneity to forecast immunotherapy response in triple-negative breast cancer through multi-scale analysis
by: Shihao Sun, et al.
Published: (2025-08-01)

Cohesive data analysis for the identification of prognostic hub genes and significant pathways associated with HER2 + and TN breast cancer types
by: Mahrukh Zakir, et al.
Published: (2025-07-01)

CD24a knockout results in an enhanced macrophage- and CD8⁺ T cell-mediated anti-tumor immune responses in tumor microenvironment in a murine triple-negative breast cancer model
by: Shih-Hsuan Chan, et al.
Published: (2025-08-01)

Amino acids shape the metabolic and immunologic landscape in the tumor immune microenvironment: from molecular mechanisms to therapeutic strategies
by: Ziyou Lin, et al.
Published: (2025-07-01)

HEREDITARY BREAST CANCER
by: E. M. Bit-Sava, et al.
Published: (2016-02-01)

Metaplastic carcinoma of the breast: A case series and review of the literature
by: Deniz Eren Böler, et al.
Published: (2016-08-01)

Effect and clinical mechanism exploration of acupuncture intervention for chemotherapy-related cognitive impairment (CRCI) in triple-negative breast cancer: study protocol for a randomized controlled trial
by: Wenqi Yang, et al.
Published: (2025-07-01)

SHCBP1 drives tumor progression in triple-negative breast cancer
by: Huiling Wang, et al.
Published: (2025-07-01)

Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomes
by: Matthew Dankner, et al.
Published: (2025-08-01)

A smart all-in-one strategy based on hybrid bacteria with targeting drug delivery and spatiotemporal drug release to boost the synergistic therapeutic efficacy against TNBC
by: Wenzhe Yuan, et al.
Published: (2025-06-01)

Clinical case of torpid course of metastatic triple negative breast cancer
by: E. P. Kulikov, et al.
Published: (2022-03-01)

PML localization in tumor associated macrophages as a prognostic marker in triple negative breast cancer
by: Bianca Vezzani, et al.
Published: (2025-07-01)

Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial
by: Vinod K. Ramani, et al.
Published: (2025-08-01)

Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study
by: Beate Vajen, et al.
Published: (2025-05-01)

Targeting LAT1 with JPH203 to reduce TNBC proliferation and reshape suppressive immune microenvironment by blocking essential amino acid uptake
by: Yajie Zhao, et al.
Published: (2025-05-01)

Editorial: The immune infiltrate as a paradigm model to study the biology and novel therapeutic approaches in sarcomas, volume II
by: Silvia Vanni, et al.
Published: (2025-05-01)

Interleukin-10: A double-edged sword in breast cancer
by: Chun-Ming Chang, et al.
Published: (2021-01-01)

Response of MDA-MB231 cells to cisplatin and paclitaxel — viability, migration and gene expression estimation in mono- and co-culture with macrophages
by: Brygida Rusiecka, et al.
Published: (2025-01-01)

Pharmacological mechanisms of berberine against triple negative breast cancer: Integration of network pharmacology and experimental validation
by: Tian Qin, et al.
Published: (2025-08-01)

Dual-ferroptosis induction-based microneedle patches for enhanced chemodynamic/photothermal combination therapy against triple-negative breast cancer
by: Yujie Wang, et al.
Published: (2025-08-01)

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
by: Jieun Lee, et al.
Published: (2025-08-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in China
by: Yibing Hou, et al.
Published: (2025-08-01)

Chemotherapeutic drug scavenger-based combination therapy toward treating triple-negative breast cancer
by: Qingqing Yin, et al.
Published: (2025-07-01)

Adenoid cystic carcinoma of the breast, from diagnosis to management: a case report
by: Diana Marcela Mendoza-Urbano, et al.
Published: (2025-01-01)

SYNTHESIS, CHARACTERISATION, AND INVESTIGATION OF THE ANTICANCER POTENTIAL OF CARMOFUR-LOADED SILVER NANOPARTICLES
by: Ferdane Danışman Kalındemirtaş, et al.
Published: (2025-04-01)

FEATURES OF CYTOKINE-MEDIATED REGULATION OF FOCAL AND SYSTEMIC INFLAMMATION IN COPD
by: E. A. Surkova, et al.
Published: (2014-07-01)

RBM15 enhances paclitaxel resistance in triple-negative breast cancer by targeting m6A methylation of TNFSF9 and inducing polarization of tumor-associated macrophages to M2 phenotype
by: Jinkun Fu, et al.
Published: (2025-08-01)

A Preliminary Study on the Therapeutic Role of γδT Cells in Triple‐Negative Breast Cancer
by: Shi Qiu, et al.
Published: (2025-08-01)

Role of proteasome system in prognosis of breast cancer progression
by: E. E. Shashova, et al.
Published: (2018-09-01)

MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer
by: Roberto Dinami, et al.
Published: (2022-11-01)

CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms
by: Liu Haiyan, et al.
Published: (2025-08-01)

Molecular biological subtypes of breast cancer in BRCA1 mutation carriers
by: N. I. Pospekhova, et al.
Published: (2021-01-01)